Scientific Publications Search Search Author Impact Factor Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Bunse, Mario Dr. (3) Chen, Wei Prof. Dr. (1) Edes, Inan Dr. (1) Gavvovidis, Ioannis Dr. (1) Ivics, Zoltan Dr. (1) Izsvak, Zsuzsanna Dr. (2) Kettenmann, Helmut Prof. Dr. (2) Kieback, Elisa Dr. (2) Ku, Min-Chi Dr. (1) Leisegang, Matthias Dr. (6) Lorenz, Felix Dr. (4) Niendorf, Thoralf Prof. Dr. (1) Obenaus, Matthias (1) Poncette, Lucia (1) Singh, Manvendra Dr. (1) Uckert, Wolfgang Prof. Dr. (20) Waiczies, Helmar Dr. (1) Waiczies, Sonia Dr. (1) Wolf, Susanne Dr. (1) (-) Blankenstein, Thomas Prof. Dr. (6) 1998 (2) 2000 (2) 2003 (4) 2004 (1) 2005 (3) 2006 (2) 2007 (1) 2008 (1) 2010 (1) (-) 2011 (2) 2014 (1) (-) 2015 (2) (-) 2016 (1) 2017 (1) (-) 2019 (1) Bioinformatics (1) Biology of Malignant Lymphomas (14) Genetics and Genomics of Cardiovascular Diseases (2) Immune Regulation and Cancer (1) (-) Molecular Cell Biology and Gene Therapy (6) Molecular Immunology and Gene Therapy (18) Molecular Immunotherapy (3) Proteome Dynamics (1) Signal Transduction in Tumor Cells (2) Structural Biology of Membrane-Associated Processes (1) Systems Biology of Gene Regulatory Elements (1) 6 Results: Active Filter: Blankenstein, Thomas Prof. Dr.Molecular Cell Biology and Gene Therapy2011201520162019 Sort: Result score Newest to oldest Oldest to newest January 02, 2019 in J Clin Invest Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression L. Poncette X. Chen F.K.M. Lorenz T. Blankenstein March 01, 2016 in J Clin Invest Targeting human melanoma neoantigens by T cell receptor gene therapy M. Leisegang T. Kammertoens W. Uckert T. Blankenstein April 01, 2015 in Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein April 01, 2015 in Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber July 28, 2011 in Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein January 15, 2011 in Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
January 02, 2019 in J Clin Invest Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression L. Poncette X. Chen F.K.M. Lorenz T. Blankenstein
March 01, 2016 in J Clin Invest Targeting human melanoma neoantigens by T cell receptor gene therapy M. Leisegang T. Kammertoens W. Uckert T. Blankenstein
April 01, 2015 in Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein
April 01, 2015 in Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber
July 28, 2011 in Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
January 15, 2011 in Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
